Aerpio Pharmaceuticals: Is This Stock A Buy Or Sell? Not Until The Merger Is Over


  • Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company that is developing compounds that activate Tie2 for various indications but has recently entered into a merger with privately-held Aadi Bioscience.
  • Aadi is a private clinical-stage biopharmaceutical company developing precision therapies for genetically defined cancers with alterations in mTOR pathway genes and currently awaiting NDA results.
  • Aerpio and Aadi entered into an agreement on May 2021 for a merger where Aerpio stockholders will only own 14.7% of the new entity expected to finalize in 2H 2021.
  • Aerpio and Aadi’s consolidated financials outline an expected post-merger cash position of $182.6M (incl. of PIPE) with sales expected to reach $7M in 2023 growing up to $2.5B by 2030.
  • In summary, the author projects Aerpio Pharmaceuticals, Inc. as a “hold” until after the Merger.

Putting test tubes into the holder
RossHelen/iStock via Getty Images

Graphic Source: Aerpio Pharmaceuticals, Inc.

Introduction: What is Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) is a biopharmaceutical company developing compounds that active Tie2 for various indications including Open Angle Glaucoma, COVID-19, Diabetic Nephropathy, IBD, and more. Aerpio recently announced its

Data by YCharts

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Leave a Reply

Your email address will not be published. Required fields are marked *